A phenome-wide association study to discover pleiotropic effects of PCSK9, APOB, and LDLR

[1]  T. Hankemeier,et al.  Genome-wide association study of plasma lipids , 2019, bioRxiv.

[2]  M. Rivas,et al.  Large-Scale Phenome-Wide Association Study of PCSK9 Variants Demonstrates Protection Against Ischemic Stroke , 2018, Circulation. Genomic and precision medicine.

[3]  Spiros C. Denaxas,et al.  Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9 , 2018, bioRxiv.

[4]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[5]  D. Strachan,et al.  The low single nucleotide polymorphism heritability of plasma and saliva cortisol levels , 2017, Psychoneuroendocrinology.

[6]  Raquel S. Sevilla,et al.  Exome-wide association study of plasma lipids in >300,000 individuals , 2017, Nature Genetics.

[7]  N. Cox,et al.  Evaluating phecodes, clinical classification software, and ICD-9-CM codes for phenome-wide association studies in the electronic health record , 2017, PloS one.

[8]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[9]  Marylyn D. Ritchie,et al.  A simulation study investigating power estimates in phenome-wide association studies , 2017, BMC Bioinformatics.

[10]  Jennifer G. Robinson,et al.  Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials. , 2017, Journal of the American College of Cardiology.

[11]  Hynek Pikhart,et al.  PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study , 2017, The lancet. Diabetes & endocrinology.

[12]  T. Farid,et al.  Increased Risk of Adverse Neurocognitive Outcomes With Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors , 2017, Circulation. Cardiovascular quality and outcomes.

[13]  Szilard Voros,et al.  Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. , 2016, The New England journal of medicine.

[14]  Sara M. Willems,et al.  Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis. , 2016, JAMA.

[15]  Alan M. Kwong,et al.  Next-generation genotype imputation service and methods , 2016, Nature Genetics.

[16]  Dave L Dixon,et al.  A review of PCSK9 inhibition and its effects beyond LDL receptors. , 2016, Journal of clinical lipidology.

[17]  N. Eriksson,et al.  Genome-wide association and HLA region fine-mapping studies identify susceptibility loci for multiple common infections , 2016, Nature Communications.

[18]  D. Roden,et al.  Phenome-Wide Association Studies as a Tool to Advance Precision Medicine. , 2016, Annual review of genomics and human genetics.

[19]  Jennifer G. Robinson,et al.  No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies , 2016, European heart journal.

[20]  R. Santos,et al.  Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns? , 2016, Atherosclerosis.

[21]  S. Yusuf,et al.  Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. , 2016, The New England journal of medicine.

[22]  R. Ferré,et al.  Circulating PCSK9 in patients with type 2 diabetes and related metabolic disorders. , 2016, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

[23]  S. Fortmann,et al.  Dyslipidemia in Special Ethnic Populations. , 2016, Endocrinology and metabolism clinics of North America.

[24]  Dana C. Crawford,et al.  Unravelling the human genome–phenome relationship using phenome-wide association studies , 2016, Nature Reviews Genetics.

[25]  Gerard Tromp,et al.  The phenotypic legacy of admixture between modern humans and Neandertals , 2016, Science.

[26]  H. Brewer,et al.  The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. , 2016, European heart journal.

[27]  Jennifer G. Robinson,et al.  Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. , 2015, The New England journal of medicine.

[28]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[29]  B. Balkau,et al.  The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis , 2015, Diabetologia.

[30]  S. Fortmann,et al.  Dyslipidemia in special ethnic populations. , 2015, Cardiology clinics.

[31]  Jennifer G. Robinson,et al.  Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. , 2015, The New England journal of medicine.

[32]  H. Tiwari,et al.  PCSK9 variation and association with blood pressure in African Americans: preliminary findings from the HyperGEN and REGARDS studies , 2015, Front. Genet..

[33]  Simon M Lin,et al.  Opportunities for drug repositioning from phenome-wide association studies , 2015, Nature Biotechnology.

[34]  J. Kastelein,et al.  Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. , 2015, JAMA.

[35]  P. Elliott,et al.  UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age , 2015, PLoS medicine.

[36]  P. Bayrak-Toydemir,et al.  Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era , 2015, Front. Genet..

[37]  James T. Elder,et al.  Genome-wide Comparative Analysis of Atopic Dermatitis and Psoriasis Gives Insight into Opposing Genetic Mechanisms , 2015, American journal of human genetics.

[38]  Paolo Vineis,et al.  A genome-wide association study of marginal zone lymphoma shows association to the HLA region , 2015, Nature Communications.

[39]  Marylyn D. Ritchie,et al.  Detection of Pleiotropy through a Phenome-Wide Association Study (PheWAS) of Epidemiologic Data as Part of the Environmental Architecture for Genes Linked to Environment (EAGLE) Study , 2014, PLoS genetics.

[40]  M. Frye,et al.  Bipolar disorder with comorbid binge eating history: a genome-wide association study implicates APOB. , 2014, Journal of affective disorders.

[41]  Joshua C. Denny,et al.  R PheWAS: data analysis and plotting tools for phenome-wide association studies in the R environment , 2014, Bioinform..

[42]  Weiliang Qiu,et al.  Integrated genome-wide association, coexpression network, and expression single nucleotide polymorphism analysis identifies novel pathway in allergic rhinitis , 2014, BMC Medical Genomics.

[43]  N. Seidah,et al.  PCSK9: A Key Modulator of Cardiovascular Health , 2014, Circulation research.

[44]  Zhi-Sheng Jiang,et al.  The dual behavior of PCSK9 in the regulation of apoptosis is crucial in Alzheimer's disease progression (Review). , 2014, Biomedical reports.

[45]  Jennifer G. Robinson,et al.  Whole-exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol. , 2014, American journal of human genetics.

[46]  P. Jose,et al.  Racial/Ethnic Differences in Dyslipidemia Patterns , 2014, Circulation.

[47]  Peggy Hall,et al.  The NHGRI GWAS Catalog, a curated resource of SNP-trait associations , 2013, Nucleic Acids Res..

[48]  W. Cromwell,et al.  Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. , 2013, Journal of the American College of Cardiology.

[49]  B. Nordestgaard,et al.  Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study. , 2013, The lancet. Diabetes & endocrinology.

[50]  C. Frei,et al.  Association of statin use with cataracts: a propensity score-matched analysis. , 2013, JAMA ophthalmology.

[51]  Xiang Wang,et al.  Cholesterol Levels and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis , 2013, Stroke.

[52]  Melissa A. Basford,et al.  The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future , 2013, Genetics in Medicine.

[53]  C. Haley,et al.  The heritability of human disease: estimation, uses and abuses , 2013, Nature Reviews Genetics.

[54]  Marylyn D. Ritchie,et al.  Phenome-Wide Association Study (PheWAS) for Detection of Pleiotropy within the Population Architecture using Genomics and Epidemiology (PAGE) Network , 2013, PLoS genetics.

[55]  XiangWang,et al.  Cholesterol Levels and Risk of Hemorrhagic Stroke , 2013 .

[56]  Vaneet Lotay,et al.  Can Genetic Pleiotropy Replicate Common Clinical Constellations of Cardiovascular Disease and Risk? , 2012, PloS one.

[57]  S. Seal,et al.  A genome-wide association study identifies susceptibility loci for Wilms tumor , 2012, Nature Genetics.

[58]  F. Agakov,et al.  Abundant pleiotropy in human complex diseases and traits. , 2011, American journal of human genetics.

[59]  Wendy A. Wolf,et al.  The eMERGE Network: A consortium of biorepositories linked to electronic medical records data for conducting genomic studies , 2011, BMC Medical Genomics.

[60]  Richard Stock,et al.  Genome-wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer. , 2010, International journal of radiation oncology, biology, physics.

[61]  Yasuo Ohashi,et al.  Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials , 2010, The Lancet.

[62]  M. Benn.  Apolipoprotein B levels, APOB alleles, and risk of ischemic cardiovascular disease in the general population, a review. , 2009, Atherosclerosis.

[63]  D. Roden,et al.  Development of a Large‐Scale De‐Identified DNA Biobank to Enable Personalized Medicine , 2008, Clinical pharmacology and therapeutics.

[64]  Jonathan C. Cohen,et al.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.

[65]  C. McCarty,et al.  Marshfield Clinic Personalized Medicine Research Project (PMRP): design, methods and recruitment for a large population-based biobank. , 2005, Personalized medicine.

[66]  D. Bloch,et al.  A simple method of sample size calculation for linear and logistic regression. , 1998, Statistics in medicine.

[67]  Ron Kohavi,et al.  A Study of Cross-Validation and Bootstrap for Accuracy Estimation and Model Selection , 1995, IJCAI.

[68]  H. Kipen,et al.  Questions and Answers 1 , 1994 .